Purpose: To investigate whether the three single nucleotide polymorphisms (SNPs), SNP-43, -56, and -63 of CAPN10 were associated with type 2 diabetes in a West African cohort.
Methods: A total of 347 diabetic subjects and 148 unaffected controls from four ethnic groups in two West African countries were enrolled in this study. After genotyping three SNPs of CAPN10 and one SNP from CYP19, the allele, genotype, and haplotype frequencies as well as the odds ratios were calculated to test their association with type 2 diabetes.
Results: None of the alleles or genotypes was associated with type 2 diabetes. Although statistical analysis indicated that haplotype 221 was associated with type 2 diabetes (OR, 3.765; 95% CI, 1.577-8.989) in the two ethnic groups of Nigeria, the same haplotype did not show any association with type 2 diabetes in the two ethnic groups in Ghana (OR, 0.906; 95% CI, 0.322-2.552).
Conclusion: Considering the relatively low frequency of haplotype 221 and that none of the haplotypes including 221 was associated with any of the diabetes-related quantitative traits tested, it is concluded that SNP-43, -56, and -63 of the CAPN10 gene variants may play a limited role in the risk of type 2 diabetes risks in this cohort of West Africans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annepidem.2004.05.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights.
Cytotherapy
November 2024
Department of Translational and Precision Medicine, University of Rome, Rome, Italy. Electronic address:
Cellular and gene therapy (CGT) products have emerged as a popular approach in regenerative medicine, showing promise in treating various pancreatic and liver diseases in numerous clinical trials. Before these therapies can be tested in human clinical trials, it is essential to evaluate their safety and efficacy in relevant animal models. Such preclinical testing is often required to obtain regulatory approval for investigational new drugs.
View Article and Find Full Text PDFExploring Chronic Pain in Hemodialysis Patients: An Observational Study Based on the New IASP Classification for ICD-11.
Pain Ther
January 2025
Department of Medicine, Nephrology Division, University of Verona, Verona, Italy.
Introduction: Pain is one of the most frequently reported symptoms in hemodialyzed (HD) patients, with prevalence rates between 33% and 82%. Risk factors for chronic pain in HD patients are older age, long-lasting dialysis history, several concomitant diseases, malnutrition, and others. However, chronic pain assessment in HD patients is rarely performed by specialists in pain medicine, with relevant consequences in terms of diagnostic and treatment accuracy.
View Article and Find Full Text PDFEating disorders among people with and without type 1 diabetes: incidence and treatment in a nationwide population-based cohort.
Diabetologia
January 2025
Department of Public Health, University of Helsinki, Helsinki, Finland.
Aims/hypothesis: Eating disorders are over-represented in type 1 diabetes and are associated with an increased risk of complications, but it is unclear whether type 1 diabetes affects the treatment of eating disorders. We assessed incidence and treatment of eating disorders in a nationwide sample of individuals with type 1 diabetes and diabetes-free control individuals.
Methods: Our study comprised 11,055 individuals aged <30 who had been diagnosed with type 1 diabetes in 1998-2010, and 11,055 diabetes-free control individuals matched for age, sex and hospital district.
Impact of hypertension on changes in peripapillary retinal nerve fiber layer thickness in type 2 diabetes patients.
Sci Rep
January 2025
Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Republic of Korea.
To determine longitudinal changes in the peripapillary retinal nerve fiber layer (pRNFL) thickness in type 2 diabetes mellitus (T2DM) patients with hypertension (HTN). Participants were divided into three groups: normal controls (Group 1), patients with T2DM (Group 2), and patients with both T2DM and HTN (Group 3). Following the initial examination, patients underwent three additional examinations at 1-year intervals.
View Article and Find Full Text PDFLong-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study.
Cardiovasc Diabetol
January 2025
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients with type 2 diabetes remains unclear. In patients with STEMI and type 2 diabetes, we aimed to investigate the association between long-term prognosis and GLP-1RA treatment before STEMI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!